The abnormal adherence of red blood cells (RBCI t o the blood vessel wall is believed t o contribute t o the vascular occlusion observed in patients with sickle cell anemia. The cell adhesion receptors GPIV (CD36) and integrin U& (CD49d/CD291 were previously identified on circulating sickle reticulocytes, and shown t o mediate sickle RBC adhesion t o the endothelium. The presence of damaged endothelium in these patients suggests that exposed extracellular matrix proteins could provide a potential substrate for sickle RBC adhesion. To determine whether RBC adhesion receptors could mediate adhesion to extracellular matrix proteins, we tested their ability t o adhere t o a variety of immobilized, purified proteins under flow conditions. Neither sickle nor normal RBC adhered t o fibronectin, vitronectin, fibrinogen, ICKLE CELL anemia is characterized by episodic, local-S ized, vaso-occlusive crises, and by chronic hemolytic anemia that often results in significant levels of reticulocytes in the peripheral circulation.' Tissue ischemia and infarction caused by vascular occlusion result in significant morbidity and mortality in this di~ease.~.' Originally, vaso-occlusion was believed to be caused by passive blockage of the microvasculature with poorly deformable sickle erythrocytes. Substantial evidence now indicates that abnormal adherence of sickle red blood cells (RBC) to the vascular endothelium probably contributes to vaso-oc~lusion.'~~~~ It has been proposed that adhesion of reticulocytes and young erythrocytes to the endothelium could precipitate vessel occlusion by retarding the flow through capillaries of other RBC, especially dense cells that have an increased tendency to sickle in a deoxygenated environment?'
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vascular cell adhesion molecule-1 (VCAM-I)." In addition, a4Pl on phorbol myristate acetate (PMA)-activated T cells recognizes TSP." In both flowing and static adhesion assays, TSP promotes sickle cell adhesion to cultured endothelium, apparently by acting as a bridging molecule between reticulocyte GPIV and endothelial cell GPIV or integrin a,P3.'0.' 8 It has also been observed under flow conditions that a4PI on sickle cells mediates sickle cell binding to FN on unstimulated endothelium'' and to VCAM-1 on cytokine-stimulated endothelium.' ' Endothelial cell damage, possibly caused by ischemia or sickle RBC interactions, has been documented in sickle cell patients." Elevated numbers of circulating endothelial cells measured in patients in vaso-occlusive crisis is a further indication of damaged end~thelium.~' Proteins including TSP, FN, von Willebrand factor, vitronectin (VN), and collagens among other elements comprise the extracellular matrix (ECM) underlying the endothelium? Damage and/or detachment of the endothelium would expose ECM, providing a rich substrate for potential sickle RBC adhesion. Moreover, exposed ECM would be expected to bind proteins such as fibrinogen (FB) from flowing blood. 23 To identify proteins that could potentially initiate sickle RBC adhesion to the ECM, we measured sickle RBC adhesion to immobilized purified proteins. Sickle RBC adhesion was measured under controlled flow conditions, which more closely simulate many of the dynamic variables present under venous conditions in vivo. Of the proteins tested here, sickle RBC adhered only to TSP; however, neither GPIV nor (u4P1 were found to mediate this adhesion. Interestingly, sickle RBC adhesion was substantially inhibited by the glycosaminoglycans, chondroitin sulfate A (CSA) and dextran sulfates (DS), suggesting that a distinct mechanism mediates sickle RBC adhesion to immobilized TSP under these conditions.
MATERIALS AND METHODS

Reagents.
Purified proteins used in this study were obtained from several sources. FN was purified from pooled plasma following a combination of methods including gelatin affinity chromatography as de~cribed?~ or purchased from GIBCO (Grand Island, NY). FB was purified from fresh human plasma as previously described.*' TSP from human platelets was generously provided by J. Lawle8' 4 , and filtered through a 0 . 1~ filter). For experiments involving reticulocyte enriched and depleted fractions, cells were obtained from washed RBC (unpacked) using a modified arabinogalactan density gradient procedure" as described? RBC from the top 20% and bottom 5% of the gradient were collected, washed to remove gradient material, packed, and resuspended to a hematocrit of 1% in SFM, for use in the adhesion assay. Reticulocytes (as identified by methylene blue staining) represented from 10% to 80% of the cells in the top fraction, and less than 5% in the bottom fraction. All RBC preparations were used in the flow adhesion assays immediately following isolation.
The dynamic flow adhesion system used for this study consists of a modified parallel plate flow chamber designed by J. Moake and L. McIntire (Rice University, Houston, TX), and has been used to study RBC and leukocyte interactions with the endothelium under conditions of controlled flow. The flow chamber serves as a simplified model of a blood vessel, where a laminar flow is created between two parallel plates. As fluid moves through the chamber, a velocity gradient or shear rate develops that can model rates occumng in the microvasculature. The upper plate of the flow chamber, which contains entry and exit ports for the cell RBC isolation.
Flow adhesion assay.
suspension, is circular and constructed of clear lexan. This fits tightly into the lower plate of the chamber that is formed by a 35-mm2 tissue culture dish containing immobilized proteins. The depth of the chamber is regulated by the thickness (0.025 cm) of a silicon gasket (Specialty Manufacturing Inc, Hemlock, MI) located between the two plates. The sides of the flow chamber are created by the gasket with two wells cut into the gasket so that two independent conditions can be examined.
The assembled chamber was mounted on the stage of an inverted phase-contrast microscope (Model CK-2; Olympus, Tokyo, Japan), which allows for continuous visual monitoring of RBC adhesion. The flow chamber was kept at 37°C by a Plexiglass enclosure that surrounds the microscope and contains an intemal heating element, a thermocouple mounted in a solution of SFM on the stage, and a fan that continuously circulates the air. Temperature is controlled by an external thermocouple controller (Omega Engineering, Stanford, CT) that monitors the temperature of the SFM via the thermocouple, and appropriately adjusts the current to the heating element. Media and RBC suspensions are kept at 37°C in an adjacent water bath until added to the reservoir located in the Plexiglass enclosure. The cell suspension is placed in the reservoir and drawn through medical grade silicon tubing (Silastic; Dow Coming, Midland, MI), into the flow chamber at a controlled flow rate (0.25 mL/min) by an external peristaltic pump (Minipuls; Gilson, Middleton, WI).
RBC adhesion to immobilized proteins was measured under continuous flow conditions without static incubations. RBC adhesion was measured at a constant shear stress of 1 dyne/cm2 where in vitro sickle cell adhesion has been o b~e r v e d . * .~'~~~ This shear stress has been measured in postcapillary venules:' where sickle cell adhesion is observed to occur in physiological flow systems. 34 The wall shear stress (7) in the flow chamber was estimated assuming a fully developed flow of a Newtonian fluid throughout parallel-plate geometry using the following equation: T = 6 pQ/a2b (dynedcm') where p is the fluid viscosity (dynes. s/cm2), Q is the flow rate (musec), a is the chamber depth (cm), and b is the chamber width (cm)?'
To examine RBC adhesion to proteins, 35 mm2 culture dishes containing immobilized proteins were gently washed 3 times with SFM, and the top of the flow chamber containing the gasket was placed into the culture dish and secured initially with a low vacuum around the outer perimeter. After a seal was established, the vacuum was removed to avoid any potential distortion of the flow during the experiment. The immobilized proteins were washed for 3 minutes, and 1.5 mL of the RBC suspension at a 1% hematocrit was added to the reservoir and allowed to flow for 6 minutes over the chamber substrate, followed by a 9 minute wash with SFM. Adherent RBC, in a 0.25 mm2 field, as defined by an ocular grid (0.5 mm X 0.5 mm) under lOOX power, were counted from four representative areas around the center line of the chamber, averaged, and normalized to cells/mm2. The Caz+ and Mg2+ concentrations in HBSS were 1.3 mmoVL and 0.8 mmol/L, respectively. HBSS was used because the addition of 1 mmoUL Ca2+ to some media, (eg, RPMI) results in an insoluble salt precipitate that enhances TSP binding to several cell lines. 36 Proteins were immobilized to the tissue culture treated surface of the wells formed by the silicon gasket, which was attached to the surface of the 35 mm2 tissue culture treated dish with a Light coating of vacuum grease. Each well was incubated for 60 minutes at 37°C with 75 pL of the appropriate buffer containing the following amounts of proteins: TSP (0.1 to 1.5 pg); FN, VN, FB, COL (2.5 pg). The protein concentrations when calculated using the area of each well (0.76 cm2) were 0.132 to 3.29 pglcm2, which is within the range reported to support adhesion of several cell types. TSP was diluted in TSP buffer (15 mmoVL Tris, pH 7.4, 141 mmoUL NaCI, 2 mmoVL CaCI2, 0.02% azide), collagen diluted in 10 mmoV L acetic acid, and all other proteins were diluted in PBS. Subsequent
For personal use only. on October 23, 2017. by guest www.bloodjournal.org From treatment of protein-coated wells with 2% BSA did not affect RBC adhesion when compared with unblocked wells, indicating that BSA blocking was unnecessary. All subsequent manipulations involving TSP were performed in the presence of Ca2'-containing buffer, because Ca" is required to maintain the native conformation of TSP.
After incubation, the wells were washed three times with the appropriate buffer in which they were stored before use in the adhesion assay.
All proteins used in the flow adhesion experiments were capable of supporting cell adhesion, because activated platelets and EA926 cells (immortalized endothelial cells kindly provided by C.J. Edgell, University of North Carolina at Chapel Hill) adhered to the immobilized proteins in a static adhesion assay (data not shown) In addition, microscopic examination of VN-, EN-, and FB-coated flow chamber wells stained with Wright-Giemsa after completion af flow experiments revealed the presence of adherent leukocytes. This suggests that proteins remained immobilized on the tissue culture-treated surface in a functional form throughout the adhesion experiments.
To 
RESULTS
Sickle RBCs adhere to immobilized TSP. Using the flow adhesion assay under conditions that model shear stress observed in postcapillary venules (1 dynelcm'), ECM candidate proteins were assayed for those that would support sickle RBC adhesion. We observed substantial adhesion (322 -+ 37.9 cells/mm*, mean t SEM) of sickle RBC to immobilized TSP but not to other proteins tested (Fig 1) . RBC adhered to TSP in a concentration-dependent manner, with maximal adhesion occurring at a protein plating amount of 1.5 bg/ well (data not shown). Sickle RBC with normal as well as "sickled shape" morphology that is characteristic of irreversibly sickled cells, adhered to TSP. Sickle RBC were also observed to slide across collagen, reminiscent of the rolling behavior exhibited by leukocyte^.^' Nonspecific adhesion of sickle RBC to an irrelevant protein, BSA, was less than 25 RBC/mm2, as was adhesion for RBC from normal volunteers to all proteins tested.
Absence of sickle RBC adhesion to fibronectin suggests that the a4PI receptor on reticulocytes may exist in insufficient density or in an inactive state toward FN. Because integrin a4PI can exist in an inactive form that is unable to bind ligand, prior stimulation of sickle RBC for 20 minutes with 1 pmoVL of the phorbol ester, PMA, a known activator of this integrin in other cell types, was used in an attempt to promote RBC adhesion to FN. PMA treatment of sickle RBC from 15 different patients did not result in enhanced adhesion to immobilized FN (Fig 1) . However, immobilized Sickle RBC adhesion to TSP was specific as determined by several criteria. Preincubation of immobilized TSP with increasing concentrations of an anti-TSP pAb inhibited sickle RBC adhesion in a concentration-dependent manner, while preincubation with equivalent concentrations of a control pAb had minimal inhibitory effects (Fig 2A) . Because TSP has an obligatory Ca2+ requirement to maintain its native conformation and support cell adhesion, chelation can be used as one means of determining if RBC adhesion is specific for TSP.38 Pretreatment of TSP with 5 mmol/L EDTA before immobilization substantially eliminated RBC adhesion in comparison to untreated TSP (Fig 2B) . The lack of RBC adhesion to EDTA-treated TSP did not result from decreased amounts of immobilized TSP because equivalent amounts of TSP or EDTA-treated TSP were detected with anti-TSP MoAb in an enzyme linked immunosorbent assay (ELISA) (data not shown). In addition, equivalent amounts of '"I-TSP have previously been shown to adhere to surfaces in the presence or absence of 5 mmoVL EDTA. 38 RBC attachment was characteristic of cell adhesion to TSP, and not likely to result from any potential contaminant or from a nonspecific interaction.
Antagonists of the GPIV-TSP interaction do not inhibit sickle RBC adhesion. Reticulocyte-enriched RBC populations obtained by density gradient fractionation were significantly more adherent to immobilized TSP than reticulocyte-depleted RBC, (61 1 t 132 v 232 2 50 cells/mm' mean tive of reticulocytes being the more adhesive population. However, because the reticulocyte-enriched RBC fractions contain small percentages of mature erythrocytes, and the reticulocyte-depleted fractions exhibit measurable adhesion to TSP, it is also possible that more mature erythrocytes may adhere to TSP (Fig 3) . Thus, although it can be concluded that the less dense (reticulocyte-enriched) fraction is more adhesive, an exact identification of the adherent cells would be required to more precisely determine the most adhesive subpopulation of sickle RBC.
To determine whether GPIV contributes to sickle RBC adhesion under flow conditions, we examined the ability of anti-GPIV antibodies to inhibit the GPIV adhesion to TSP. An anti-GPIV MoAb previously defined to block TSP binding to GPIV, OKM-5, failed to inhibit sickle RBC adhesion ( P > .IO for each concentration) when used at concentrations (6.6 to 20.0 pg/mL) reported to inhibit cell adhesion ( Fig   4A) . Although an anti-GPIV pAb decreased RBC adhesion to TSP, a control pAB decreased RBC adhesion to the same extent (20 pg/mL, 364 t 9 v 400 2 39 cells/mm2, mean t SEM, P > .20; 50 pg/mL; 366 t 69 v 31 1 t 77 cells/ mm2, P > .IO), indicating that the inhibition resulted from a nonspecific antibody effect (Fig 4B) . Analysis by flow cytometry showed that both OKM-5 and anti-GPIV pAb bound to sickle reticulocytes (data not shown). Furthermore, a GPIV binding site located within the type 1 repeat of TSP has been identified as the sequence CSVTCG,'".'" and has been used as a competitive inhibitor of the TSP-GPIV intera~t i o n .~' We did not observe specific inhibition of RBC adhesion to TSP with up to 1 mmolL CSVTCG peptide (data not shown) using either the standard 9-minute wash or a 2-minute wash, further supporting a GPIV-independent mechanism of binding under these conditions. Interestingly, soluble TSP at 400 pmol/L did not inhibit sickle RBC adhesion to immobilized TSP in 2 of 3 patients tested (data not shown), suggesting that immobilization of TSP results in exposure of an adhesive site that is not abundantly accessible in soluble TSP.
Integrin a4pI-TSP does nor mediate sickle RBC adhesion to TSP. Because a 4 p l reportedly recognizes TSP," we used a blocking anti-a4 MoAb to determine if sickle RBC adhesion to TSP was mediated by a 4 p l . Incubation of sickle cells with 10 to 20 pg/mL anti-human a 4 MoAb did not inhibit RBC adherence to TSP (data not shown), suggesting that adhesion to TSP is not mediated by ~~4 0 1 .
Furthermore, a 4 p l on T cells only recognizes TSP following PMA-activation, whereas sickle cell adhesion to TSP does not require activation. Moreover, because we also did not observe adhesion to FN under flow conditions, and a 4 p l recognizes FN, it is unlikely that the density of a 4 p l receptors on sickle RBC is sufficient to mediate the substantial adhesion to TSP.
Antagonists of defined adhesive sites on TSP do not inhibit sickle RBC adhesion. Inhibitors of several defined cell receptor binding sites on TSP were used in an attempt to 
5
Patients (SS) Fig 3. Reticulocyte-enriched RBC fractions are more adherent than reticulocyte-depleted RBC t o immobilized TSP. RBC isolated from sickle cell patients were separated by density on discontinuous arabinogalactan gradients, RBC from the top 20% and the bottom 5% of the gradient were removed and washed. Staining with methylene blue indicated that the least-dense fraction ( 8 ) contained reticulocytes, while the dense fraction (01 did not. Unfractionated and fractionated RBC were resuspended in SFM at a 1% hematocrit, flowed across immobilized TSP and counted as described in Fig 1. The reticulocyte-enriched fractions were more adherent than reticulocyte-depleted ( P < .01) or whole unfractionated blood ( P < .051.
Data are shown as means ? SD for five different patients.
For personal use only. on October 23, 2017. by guest www.bloodjournal.org control v experimental, Fig 5) . An ELlSA confirmed that the anti-TSP MoAb at the largest dilution used in these inhibition experiments ( I :SO) bound significantly to immobilized TSP under incubation conditions identical to those used in the adhesion assay (data not shown). Thus, epitopes on TSP identified by these MoAb, including the binding site for GPIV, do not appear to be involved in mediating sickle RBC adhesion to TSP under these conditions.
Because some cells attach to TSP via HS and CS proteoglywe investigated whether cell surface proteoglycans could be involved in sickle RBC adhesion to TSP. Several glycosaminoglycans tested including H, HS, CH, and KS did not inhibit sickle RBC adhesion (P > .OS for all noninhibitory agents). Adhesion was substantially inhibited by the sulfated glycosaminoglycan CSA (P < .Ol), but not by the CSA and DS inliibit sickle RBC adliesion to TSP. Immobilized TSP was preincubated with a combination of MoAbs A4.1, A6.1, and C6.7 (El) against various cell binding domains in TSP, or control MoAb (0) for 60 minutes at 37°C. RBC isolated from sickle cell patients were resuspended in SFM at a 1% hematocrit, flowed across immobilized TSP, and counted as described in structurally similar sulfated glycosaminoglycans CSB and CSC, which differ only in the position of the sulfate group (Fig 6) . Inhibition by CSA is concentration-dependent with an IC5o of 46.6 ? 17.8 pg/mL (n = 4; data not shown). However, CSA could not be detected immunologically on sickle RBC using MoAb CS5629 by flow cytometry (data not shown). In addition, MoAb 2B6: ' which recognized CSA and CSB on the protein aggrecan in Western blots, did not react with sickle RBC lysates or TSP by Western blots, suggesting that neither of these groups are present (data not shown). Synthetic DS also inhibited adhesion, with more substantial inhibition occurring with the high molecular weight dextrans (DS-M, P < .05; DS-L, P < .01). These results suggest that the sulfate in an appropriate molecular orientation can inhibit RBC adhesion, with probable contribution of the negative charge.
DISCUSSION
Although the initiators of vaso-occlusion are unknown, increasing evidence strongly indicates that sickle RBC adhesion to the endothelium, or possibly exposed ECM as a consequence of damaged endothelium, may contribute to the pathophysiology of vaso-occlusion in sickle cell disease. Sickle RBC adhesion to the endothelium may be sufficient to precipitate vaso-occlusion with the secondary trapping of less deformable ~ells.7.~' Another plausible hypothesis suggests that sickle RBC adhesion would delay the transit of erythrocytes through capillaries, resulting in increased frequency of cell sickling, and subsequent occlusion. 6 We used a continuous flow adhesion assay to screen immobilized proteins in an attempt to identify adhesive proteins that might initiate sickle RBC adhesion to the ECM. We observe substantial sickle RBC adhesion to immobilized TSP, but not to FN, VN, FB, or COL. The remainder of this study focused on identifying the mechanism of sickle RBC adhesion to TSP, with special attention to the role of GPIV. Using either a MoAb or peptide known to inhibit the GPIV-TSP interaction, we were unable to inhibit sickle RBC adhesion, indicating that GPIV cannot be the major mechanism of RBC adhesion to immobilized TSP under flow conditions, but that another mechanism is responsible.
Sickle RBC adhesion to TSP is specific as determined by these criteria: (1) sickle RBC adhere to three different preparations of TSP (see Materials and Methods), but not to a number of other proteins; (2) sickle RBC adhere to TSP in a concentration and saturation-dependent manner; (3) EDTA pretreatment of TSP abolishes sickle RBC adhesion (a characteristic property of cell adhesion to TSP) and (4), an anti-TSP pAb inhibits sickle RBC adhesion in a concentration-dependent manner. Enhanced adherence of the reticulocyte-enriched RBC fraction, in contrast to the reticulocytedepleted fraction, suggests that reticulocytes may be the more adhesive RBC subpopulation for sickle RBC adherence to TSP. However, because mature erythrocyte-enriched fractions also exhibit some adherence to TSP, we cannot conclusively state that reticulocytes are the more adherent subpopulation. Recently in a static adhesion assay that allowed for the identification of adherent RBC, reticulocytes were observed to adhere to immobilized TSP in substantially greater numbers than erythrocytes." Thus, current research is suggestive of reticulocytes being more adherent to TSP.
The absence of sickle RBC adhesion to FN even when sickle RBC were treated with PMA, suggests that integrin a4PI cannot mediate sickle cell adhesion to immobilized fibronectin under flow conditions. However, a weaker adhesion may occur that does not hold up under flow because it was previously reported that sickle cells adhere to FN in a static assay.48 Also, sickle cells bind to VCAM-1 on activated endothelium." HEL cell adhesion was used as a control to substantiate that a4p1 mediated adhesion could be detected.
This receptor is functionally active on human erythroid progenitors including proerythr~blasts.~~ Since approximately 4,600 a4PI receptors are present per reticulocyte: this receptor density may be insufficient to support reticulocyte adhesion to immobilized fibronectin under the present flow conditions. Similarly, we found no evidence for an a4P1 mediated adhesion to TSP, although this mode of adhesion to TSP has only been reported to occur in PMA-stimulated T cells."
All antagonists of the GPIV-TSP interaction that were tested, including anti-GPIV pAb and blocking MoAb OKM-5 and A4.1, failed to inhibit RBC adhesion to immobilized TSP in flow conditions. In contrast, evidence from a static adhesion assay identified GPIV on sickle reticulocytes as the sole mediator of adhesion to immobilized TSP." These apparently contradictory results could be attributed to differences in RBC behavior under static and flow conditions. This could result in additional or different RBC attachment mechanisms that would be operative under flow but not static conditions, as occurs with platelet adhesion to immobilized TSPSo or leukocyte adhesion to the Lewis X or Sialyl Lewis X.5' The results obtained with static assays may be indicative For personal use only. on October 23, 2017. by guest www.bloodjournal.org From of mechanisms that are involved in strengthening adhesion after RBC have adhered to the endothelium or subendothelium by distinct ligand-receptor mechanisms. Such may be the role for GPIV on RBC, because adhesion in a static system can be prevented by inhibiting the GPIV-TSP interaction."
Interestingly, although RBC do not adhere to COL, they were observed to "slide" across the substrate, similar to the rolling phenomena described for the initially weak interaction between leukocytes and the e n d~t h e l i u m .~~ Thus, COL may facilitate the initial interaction of sickle RBC with the ECM and allow for subsequent adhesion mechanisms to develop.
Although endothelial GPIV and integrin a,p3 reportedly bind TSP to mediate sickle RBC adhesion to the endothelium under flow conditions, the receptor on sickle RBC mediating the adhesion has not been identified.s2 The inability of GRGDSP peptide to inhibit sickle RBC adhesion in this study is consistent with the inability to detect any known RGD (arginine glycine aspartic acid) binding integrins of the PI, p2, or &, families on sickle RBC.9." Absence of substantial inhibition with anti-TSP MoAb C6.7 indicates that the cellular receptor(s) that recognizes the carboxy cell binding domain, does not contribute to the observed adhesion. Conflicting results regarding the involvement of specific TSP receptors on the same cell line has occurred with several cell types." Because the majority of cell adhesion to TSP involves more than one adhesive it was necessary to use inhibitors of multiple sites simultaneously. A combination of blocking anti-TSP MoAb (A4. I , A6.1, and C6.7) against distinct cellular attachment sites in TSP, including MoAb against the GPIV binding site and the carboxy terminal cellular attachment site, did not inhibit sickle RBC adhesion. However, not all known adhesive sites on TSP were blocked with this combination. We also observed that solution-phase TSP did not readily inhibit sickle cell adhesion to immobilized TSP, suggesting that the sickle cell binding sites are cryptic when TSP is in solution. A parallel situation exists with large adhesive molecules such as FB, which expresses neoepitopes and distinct binding sites when i m m o b i l i~e d .~'~~~ Sickle RBC adhesion can be substantially inhibited by certain glycosaminoglycans, specifically CSA, DS-M, and DS-L but not by others. Lack of inhibition with H, HS, and fucoidin suggests that HS proteoglycans do not mediate RBC adhesion to immobilized TSP. Inhibition by CSA and DS does suggest that a charge effect in a particular orientation can inhibit RBC adhesion. Sulfatides, or sulfated glycolipids are present in several cell types including RBC, and bind with relatively high affinity to laminin, von Willebrand, and TSP, the latter two reported to support sickle RBC adheHowever, the profile of proteoglycan inhibitors is different than those known to inhibit protein binding to immobilized sulfatides isolated from nonsickle RBC.'* The inhibitor profile observed with sickle cell adhesion could reflect the presence of a different or enriched acidic lipid or glycoprotein composition in sickle RBC versus normal RBC. Recently, sickle RBC were shown to be enriched over normal RBC with an acidic lipid having characteristics consistent with that of either a sulfatide or ganglioside, that binds TSP,'" although whether this lipid functions as a TSP receptor on sickle cells remains to be determined.
In conclusion, we have determined that immobilized TSP, a plasma and ECM protein, supports sickle RBC adhesion, thus potentially contributing to vascular occlusion in patients with sickle cell anemia. Thus, in a flow adhesion system sickle RBC attachment to TSP appears to be independent ot GPIV. These experiments provide evidence for a distinct mechanism of sickle RBC adhesion to TSP. Such a mechanism may potentially contribute to sickle cell adhesion when TSP is in an immobilized state-either as part of the ECM or when bound to cells. Further studies are required to identify which established or as yet unknown receptor(s) mediate RBC adhesion to immobilized TSP.
